IP Library Granted Patent US 7,807,173
Granted Patent B2
US 7,807,173 · App. 11/948,505 · Granted Oct 5, 2010

Influenza vaccine formulation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,807,173
App. No.
11/948,505
Granted
Oct 5, 2010
Kind
B2
Abstract

Peptide-based anti-influenza formulations against influenza are disclosed. The peptides are derived from influenza-based epitopes. The formulations are based on peptide mixtures which may be formulated so that variability is present at particular residues. The formulations can be used to prepare vaccines for preventing influenza, particularly avian influenza.

Claims (11)

1. A peptide-based immunogenic composition comprising a peptide which is SEQ ID NO: 1.

2. The composition of claim 1 further comprising at least one peptide selected from the group consisting of SEQ ID NOs: 2 to 24.

3. The composition of claim 1 further comprising a pharmaceutically-acceptable diluent or carrier.

4. The composition of claim 3 further comprising an adjuvant.

5. The composition of claim 4 wherein the adjuvant is alum.

6. An immunogenic composition comprising a mixture of isolated peptides selected from the group consisting of SEQ ID NOs: 1 to 24, said peptides representing variants of at least one variable region of an avian influenza virus HA or HA1 protein, wherein each of said variable regions comprises one or more variable amino acid residues, at least one of said variable amino acid residues is represented by two or more amino acids.

7. The immunogenic composition of claim 6 , wherein said one or more variable amino acid residues is represented by three or more amino acids.

8. The immunogenic composition of claim 6 , further comprising a peptide selected from the group consisting of SEQ ID NOs: 25 to 40.

9. The composition of claim 1 , further comprising a peptide selected from the group consisting of SEQ ID NOs: 25 to 40.

10. The composition of claim 1 , comprising peptides of SEQ ID NOs: 1 to 24.

11. The composition of claim 1 , comprising peptides of SEQ ID NOs: 1 to 40.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded May 22, 2020
From: PERCEPTIVE CREDIT HOLDINGS, LP
To: VARIATION BIOTECHNOLOGIES (US), INC.
Reel/Frame 052744/0586 →
RELEASE OF SECURITY INTEREST Recorded May 22, 2020
From: PCOF 1, LLC
To: VARIATION BIOTECHNOLOGIES (US), INC.; VBI VACCINES (DELAWARE), INC.; VARIATION BIOTECHNOLOGIES INC.
Reel/Frame 052744/0622 →
CORRECTIVE ASSIGNMENT TO CORRECT THE SEE ATTACHED INSTRUCTION SHEET DUE TO FIELD RESTRICTIONS PREVIOUSLY RECORDED ON REEL 041038 FRAME 0671. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Oct 15, 2018
From: VARIATION BIOTECHNOLOGIES (US), INC.
To: PERCEPTIVE CREDIT HOLDINGS, LP
Reel/Frame 047239/0051 →
SECURITY INTEREST Recorded Dec 20, 2016
From: VARIATION BIOTECHNOLOGIES (US), INC.
To: PERCEPTIVE CREDIT HOLDINGS, LP
Reel/Frame 041038/0668 →
SECURITY INTEREST Recorded Aug 8, 2014
From: VARIATION BIOTECHNOLOGIES (US), INC.; VBI VACCINES, INC.; VARIATION BIOTECHNOLOGIES INC.
To: PCOF 1, LLC
Reel/Frame 033501/0329 →
CHANGE OF ADDRESS Recorded Mar 27, 2012
From: VARIATION BIOTECHNOLOGIES INC.
To: VARIATION BIOTECHNOLOGIES INC.
Reel/Frame 027936/0226 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2007
From: OGREL, ANDREI, MR.
To: VARIATION BIOTECHNOLOGIES INC.
Reel/Frame 020190/0839 →